NCT01099644View on ClinicalTrials.gov

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

PHASE1TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 11, 2019

Study Completion Date

June 11, 2019

Conditions
Peritoneal Cancer
Interventions
BIOLOGICAL

131 I-8H9

Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.

Trial Locations (1)

10021

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
lead

Y-mAbs Therapeutics

INDUSTRY